# Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

> **NCT02670707** · PHASE3 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 124 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Vinblastine/prednisone

## Key facts

- **NCT ID:** NCT02670707
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-03-07
- **Primary completion:** 2027-01
- **Final completion:** 2029-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02670707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02670707, "Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02670707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*